Pressurized Intraperitoneal Aerosol Chemotherapy: The Road from Promise to Proof
- 20 January 2021
- journal article
- editorial
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (7), 1830-1832
- https://doi.org/10.1158/1078-0432.ccr-20-4342
Abstract
PIPAC is an innovative drug delivery technique for the treatment of peritoneal metastases. Its application gained popularity over the past years. Prospective clinical trials are being conducted to determine efficacy and safety. At this moment, there remain many challenges to overcome before PIPAC can be widely adopted in clinical practice.Keywords
This publication has 5 references indexed in Scilit:
- PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal MetastasesClinical Cancer Research, 2020
- A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy for advanced peritoneal metastases of gastrointestinal tract cancersEuropean Journal of Cancer, 2020
- Systemic Pharmacokinetics of Oxaliplatin After Intraperitoneal Administration by Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC) in Patients with Unresectable Colorectal Peritoneal Metastases in the CRC-PIPAC TrialAnnals of Surgical Oncology, 2020
- Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indicationsThe Lancet Oncology, 2019
- Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal CancerJournal of Clinical Oncology, 2003